Enterprise value of players in oncology rare disease therapeutics 2017
This statistic shows the enterprise value of leading pure players in rare oncology disease therapeutics worldwide as of 2017. As of that year, the value of Celgene which is specialized on multiple meloma therapeutics was around 113 billion U.S. dollars.